Ahmed El-Naas

Dr. Ahmed El-Naas


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
RIRaghad Sabaawi Ibrahim
Raghad Sabaawi Ibrahim
SIShahad Sabaawi Ibrahim
Shahad Sabaawi Ibrahim
AEAhmed El-Naas
Ahmed El-Naas
LKLenka Koklesova
Lenka Koklesova
Peter KubatkaPeter Kubatka
Peter Kubatka
Dietrich BüsselbergDietrich Büsselberg
Dietrich Büsselberg
Glioblastoma, a malignant brain tumor, is a common primary brain tumor in adults, with diabetes mellitus being a crucial risk factor. This review examines how the antidiabetic drug metformin and dietary supplement resveratrol can benefit the treatment of glioblastoma. Metformin and resveratrol have demonstrated action against relevant pathways in cancer cells. Metformin and resveratrol inhibit cell proliferation by downregulating the PI3K/Akt pathway, activating mTOR, and increasing AMPK phosphorylation, resulting in lower proliferation and higher apoptosis levels. Metformin and resveratrol both upregulate and inhibit different cascades in the MAPK pathway. In vivo, the drugs reduced tumor growth and volume. These actions show how metformin and resveratrol can combat cancer with both glucose-dependent and glucose-independent effects. The pre-clinical results, alongside the lack of clinical studies and the rise in novel delivery mechanisms, warrant further clinical investigations into the applications of metformin and resveratrol as both separate and as a combination complement to current glioblastoma therapies.